Novalis Biotech
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Pre-Seed, Seed, Early Stage, Series A
Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Luxembourg, Austria, Netherlands, Hungary, Slovenia, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia
Industries Focus
- Technology
- Health
- Medical Devices
- Biotechnology
- Nanotechnology
Investment Size:
50,000 to 4,000,000 USD
Investor Details Founded: 2018
An early-stage venture capital firm specializing in life sciences, focusing on enabling technologies.
Novalis Biotech invests in innovative research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health, supporting early-stage startups from pre-seed to Series A.
The firm emphasizes capital-light platform technologies and close interaction with customers from the early stages of a company's life, aiming to create value for stakeholders by providing funding, leveraging professional and academic connections, and shaping business strategies.
Requirements
- Innovative concepts in healthcare
- Capital-light business models
- Platform technologies in life sciences
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- BioLizard
- Cergentis
- Enzyre
- Epify
- Fertiga
- myNEO
- OHMX.bio
- Grapheal
- RheaVita
- Clouds of Care
- Alithea Genomics
- Rarity Bioscience
- RheumaFinder
Claim this Investor
Are you an official representative of Novalis Biotech?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim